

Essilor publishes an information document relating to the issuance of ordinary shares in consideration for the contribution in kind of Luxottica shares

Charenton-le-Pont, France (April 7, 2017 – 7:00 pm) – Essilor announces today the publication of an information document relating to:

- (i) A share capital increase through the issuance of ordinary Essilor shares in consideration for the contribution in kind by Delfin S.à r.l. (“**Delfin**”) of its shares in Luxottica Group S.p.A (“**Luxottica**”) and,
- (ii) The admission to trading of Essilor shares issued in connection with such contribution.

The document was registered with the French *Autorité des marchés financiers* (the “**AMF**”) under number E17-014 on April 7th, 2017 (the “**Document E**”). It incorporates by reference the 2016 Registration Document of Essilor filed with the AMF on March 30, 2017 under no. D.17-0264.

The Document E was prepared in connection with the contribution in kind by Delfin of 302,846,957 ordinary shares of Luxottica representing 62.52% of Luxottica’s share capital (as of today), to Essilor, in exchange for 139,612,447 new ordinary shares of Essilor (the “**Contribution**”), corresponding to an exchange ratio of 0.461 Essilor share for 1 Luxottica share. A listing application will be filed to admit the 139,612,447 new shares of Essilor, with a par value of €0.18 each, to trade on the Compartiment A of Euronext Paris.

The Contribution, as well as other transactions that are also part of the contemplated combination between Essilor and Luxottica, will be submitted for approval by Essilor’s General Shareholders’ Meeting convened on May 11, 2017. The prior notice of Essilor’s General Shareholders’ Meeting containing the draft resolutions to be submitted to the shareholders’ vote was published in the *Bulletin des Annonces Légales Obligatoires* (BALO) dated March 29, 2017 and completed on April 3, 2017 by the publication of the draft revised by-laws of the Company (that would be applicable following the completion of the Contribution).

Essilor draws the public’s attention to the risks factors included in the Document E (Section 3.3. “Risk Factors”) and in the 2016 Registration Document (Chapter 1.6 “Risk Factors”).

The Document E as well as the 2016 Registration Document are available free of charge at Essilor’s registered office (147, rue de Paris – 94220 Charenton-le-Pont, France), on the websites of Essilor (www.essilor.com) and of the AMF (www.amf-france.org) or by contacting Essilor’s Investor Relations team at +33(0) 1 49 77 42 16 / invest@essilor.com.

About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant®, Bolon™ and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals. Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world. For more information, please visit www.essilor.com.

The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

CONTACTS

Investor Relations and

Financial Communications

Tel: +33 (0)1 49 77 42 16

Corporate Communications

and Media Relations

Tel: +33 (0)1 49 77 45 02